GO
Loading...

The Next Big Thing In the Battle Against Cancer?

Could it be the next big thing in the battle against cancer?

Seattle Genetics is hoping its new drug will get approval from the U.S. Food and Drug Administration by the end-summer. The drug combines a cancer cell-seeking antibody with a chemotherapy drug to target and poison tumor cells. It currently targets Hodgkin Lymphoma, but developers think the approach could be used in other cancers, too.

The FDA will make its decision by August 30. If approved, CEO Clay Siegall said the company could bring the product to market roughly one-week later.

With headquarters in Bothell, Wash., Seattle Genetics is the leader in antibody conjugates. In other words, Siegall said the company empowers antibodies.

“What we do is we attach therapeutic agents, chemotherapy agents to antibodies with a stable linker and then these agents can then go find the cancer cells and kill them and we have a very big pipeline of [these drugs]," Siegall said. “We have 14 different drugs in clinical trials using our technology right now.”

Siegall appeared on the "Fast Money Halftime Report" from the American Society of Clinical Oncology's annual meeting in Chicago. Considered the biggest conference to bring cancer to light, Wall Street is turning its attention to companies that may have new treatments, like Seattle Genetics.

Watch the video to see the full interview with Siegall.

______________________________________________________
Got something to to say? Send us an e-mail at fastmoney-web@cnbc.com and your comment might be posted on the Rapid Recap. If you'd prefer to make a comment, but not have it published on our Web site, send those e-mails to fastmoney@cnbc.com.

Trader disclosure: On June 6, 2011, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s "Fast Money" were owned by the "Fast Money" traders; Weiss owns (TWM); Weiss owns (SDS); Weiss owns (JPM); Weiss owns (QCOM); Weiss owns (COP); Weiss owns (DVN); Weiss owns (HK); Weiss owns (AKAM); Weiss owns (BRCM); Weiss owns (HBAN); Weiss is short (SHAW); Weiss is short (SLR); Weiss is short (SWLT); Weiss is short (X); Grasso owns (AKS); Grasso owns (AMD); Grasso owns (ASTM); Grasso owns (BA); Grasso owns (BAC); Grasso owns (C); Grasso owns (D); Grasso owns (HOV); Grasso owns (JPM); Grasso owns (LIT); Grasso owns (LPX); Grasso owns (MHY); Grasso owns (NDAQ); Grasso owns (PFE); Grasso owns (PRST)

For Brian Kelly
Accounts Managed by Brian Kelly Capital owns (GLD)
Accounts Managed by Brian Kelly Capital owns (SLV)
Accounts Managed by Brian Kelly Capital owns (TLT) calls
Accounts Managed by Brian Kelly Capital owns Austrialian dollar
Accounts Managed by Brian Kelly Capital owns new zealand dollar
Accounts Managed by Brian Kelly Capital owns hong kong dollar
Accounts Managed by Brian Kelly Capital owns (IWM) puts
Accounts Managed by Brian Kelly Capital owns (USO) puts

For Steve Grasso:
Stuart Frankel & Co and it’s partners own(CSCO)
Stuart Frankel & Co and it’s partners own (CUBA)
Stuart Frankel & Co and it’s partners own (GERN)
Stuart Frankel & Co and it’s partners own (HPQ)
Stuart Frankel & Co and it’s partners own (HSPO)
Stuart Frankel & Co and it’s partners own (MU)
Stuart Frankel & Co and it’s partners own (MSFT)
Stuart Frankel & Co and it’s partners own (NYX)
Stuart Frankel & Co and it’s partners own (PFE)
Stuart Frankel & Co and it’s partners own (PRST)
Stuart Frankel & Co and it’s partners own RDC
Stuart Frankel & Co and it’s partners own (SDS)
Stuart Frankel & Co and it’s partners own UAL
Stuart Frankel & Co and it’s partners own (XRX)
Stuart Frankel & Co and it’s partners are SHORTS (QQQQ)
Stuart Frankel & Co and it’s partners own (AAPL)
Stuart Frankel & Co and its partners Are Short (AAPL)

A previous version of this story misspelled Clay Siegall.

CNBC.com with wires.

Symbol
Price
 
Change
%Change
SGEN
---

Contact Halftime Report

  • Showtimes

    Halftime Report - Weekdays 12p ET
    Fast Money - Weekdays 5p ET